WO2009005798A3 - Antifungal formulation and method of preparation - Google Patents

Antifungal formulation and method of preparation Download PDF

Info

Publication number
WO2009005798A3
WO2009005798A3 PCT/US2008/008179 US2008008179W WO2009005798A3 WO 2009005798 A3 WO2009005798 A3 WO 2009005798A3 US 2008008179 W US2008008179 W US 2008008179W WO 2009005798 A3 WO2009005798 A3 WO 2009005798A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
amino acid
acid sequence
preparation
fungal
Prior art date
Application number
PCT/US2008/008179
Other languages
French (fr)
Other versions
WO2009005798A2 (en
WO2009005798A8 (en
Inventor
David J Cheng
Frank G Oppenheim
Eva J Helmerhorst
Original Assignee
Pacgen Biopharmaceuticals Corp
Univ Boston
David J Cheng
Frank G Oppenheim
Eva J Helmerhorst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacgen Biopharmaceuticals Corp, Univ Boston, David J Cheng, Frank G Oppenheim, Eva J Helmerhorst filed Critical Pacgen Biopharmaceuticals Corp
Publication of WO2009005798A2 publication Critical patent/WO2009005798A2/en
Publication of WO2009005798A8 publication Critical patent/WO2009005798A8/en
Publication of WO2009005798A3 publication Critical patent/WO2009005798A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical preparation for treating a microbial infection such as a fungal or bacterial infection in an individual comprises a peptide or a pharmaceutically acceptable salt thereof, wherein said peptide has an amino acid sequence of at least 8 amino acids selected from the group of amino acid sequences consisting of the amino acid sequence of peptide P-1 13 as set forth in SEQ ID NO: 18 and various modifications thereof, wherein the buffer molarity of the pharmaceutical preparation is suitable to achieve greater than 99% killing of C. albicans in vitro. A pharmaceutical preparation for treating a microbial infection such as a fungal or bacterial infection in an individual comprises a peptide or a pharmaceutically acceptable salt thereof, wherein said peptide has an amino acid sequence of at least 8 amino acids selected from the group of amino acid sequences consisting of the amino acid sequence of peptide P-113 as set forth in SEQ ID NO: 18 and various modifications thereof, wherein the pharmaceutical preparation has a buffer molarity of about 25 mM or less. A method for treating a microbial infection such as a fungal or bacterial infection in an individual comprises administering to the individual a therapeutically effective amount of a preparation comprising a peptide or a pharmaceutically acceptable salt thereof, wherein said peptide has an amino acid sequence of at least 8 amino acids selected from the group of amino acid sequences consisting of the amino acid sequence of peptide P-113 as set forth in SEQ ID NO: 18 and various modifications thereof, wherein the buffer molarity of the preparation is suitable to achieve greater than 99% killing of C. albicans in vitro. A method for treating a microbial infection such as a fungal or bacterial infection in an individual comprises administering to the individual a therapeutically effective amount of a preparation comprising a peptide or a pharmaceutically acceptable salt thereof, wherein said peptide has an ami
PCT/US2008/008179 2007-07-03 2008-07-01 Antifungal formulation and method of preparation WO2009005798A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95821607P 2007-07-03 2007-07-03
US60/958,216 2007-07-03

Publications (3)

Publication Number Publication Date
WO2009005798A2 WO2009005798A2 (en) 2009-01-08
WO2009005798A8 WO2009005798A8 (en) 2009-03-12
WO2009005798A3 true WO2009005798A3 (en) 2009-08-13

Family

ID=40134809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/008179 WO2009005798A2 (en) 2007-07-03 2008-07-01 Antifungal formulation and method of preparation

Country Status (1)

Country Link
WO (1) WO2009005798A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130310326A1 (en) 2012-05-18 2013-11-21 Rapid Pathogen Screening, Inc. Histatin for Corneal Wound Healing and Ocular Surface Disease
US20170022256A1 (en) * 2015-07-23 2017-01-26 General Biologicals Corporation Anti-fungal and anti-bacterial peptide and therapeutic method using same
US11273124B2 (en) 2019-05-23 2022-03-15 Brown University Antifungal nanoparticles for targeted treatment of fungal infections
CN113975263B (en) * 2021-10-20 2023-06-09 河南希百康健康产业有限公司 Composition for inhibiting fungi and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040768A2 (en) * 1995-06-07 1996-12-19 Periodontix, Inc. Anti-fungal and anti-bacterial histatin-based peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631228A (en) * 1991-11-01 1997-05-20 Periodontix, Inc. Anti-fungal and anti-bacterial histatin-based peptides
WO1996040768A2 (en) * 1995-06-07 1996-12-19 Periodontix, Inc. Anti-fungal and anti-bacterial histatin-based peptides

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HELMERHORST E J ET AL: "A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 449, no. 2-3, 23 April 1999 (1999-04-23), pages 105 - 110, XP004259541, ISSN: 0014-5793 *
MICKELS N ET AL: "Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis.", JOURNAL OF CLINICAL PERIODONTOLOGY MAY 2001, vol. 28, no. 5, May 2001 (2001-05-01), pages 404 - 410, XP002532737, ISSN: 0303-6979 *
NISHIKAWA MASANOBU ET AL: "Antimicrobial activity of a chelatable poly(arginyl-histidine) produced by the ergot fungus Verticillium kibiense.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY JAN 2004, vol. 48, no. 1, January 2004 (2004-01-01), pages 229 - 235, XP002532735, ISSN: 0066-4804 *
PERDOK J F ET AL: "Physicochemical properties of commercially available mouthrinses", JOURNAL OF DENTISTRY, ELSEVIER, vol. 18, no. 3, 1 June 1990 (1990-06-01), pages 147 - 150, XP023107911, ISSN: 0300-5712, [retrieved on 19900601] *
ROTHSTEIN D M ET AL: "Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY MAY 2001, vol. 45, no. 5, May 2001 (2001-05-01), pages 1367 - 1373, XP002532736, ISSN: 0066-4804 *
XU T ET AL: "Anticandidal activity of major human salivary histatins.", INFECTION AND IMMUNITY AUG 1991, vol. 59, no. 8, August 1991 (1991-08-01), pages 2549 - 2554, XP002532734, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
WO2009005798A2 (en) 2009-01-08
WO2009005798A8 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
KR101922409B1 (en) Peptides and their use
US8466102B2 (en) Antimicrobial cationic peptides and formulations thereof
KR101306643B1 (en) Antimicrobial hexapeptides
US8324154B2 (en) Treatment of fungal infections with cyclic antimicrobial peptides
US9518093B2 (en) Topical formulation of arginine-rich cyclic antimicrobial peptides
MX2007002057A (en) Antimicrobial peptides comprising an arginine- and/or lysine-containing motif.
WO2012142320A3 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2002048183A3 (en) Compositions of peptide crystals
KR101629386B1 (en) An anti-microbial peptide Scolopendrasin-7 isolated from the Scolopendra subspinipes mutilans and its synthetic peptide
US11433028B2 (en) Compositions for treating viral infections and methods for same
KR20170052613A (en) Use of cysteamine in treating infections caused by yeasts/moulds
WO2009005798A3 (en) Antifungal formulation and method of preparation
AU2005313797A1 (en) Signal peptides, nucleic acid molecules and methods of treatment
NZ569946A (en) Cyclic peptides comprising cationic amino acids and their use as antifungals
WO2013130349A1 (en) Variants of the lantibiotic mu1140 and other lantibiotics with improved pharmacological properties and structural features
WO2008070049A8 (en) Peptide and treatment for hiv-1 infection
WO2002040529A3 (en) Diastereomeric peptides and pharmaceutical compositions comprising them
CN101415725B (en) Peptide compound with biological activity, its preparation and its application
AU2012203804A1 (en) Cyclic antimicrobial peptides
WO2022265697A1 (en) Compositions for treating viral infections and methods for same
US9408889B2 (en) Fusion peptide designed to reduce plaque bacteria and yeast in the oral cavity

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08779913

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08779913

Country of ref document: EP

Kind code of ref document: A2